Militia Capital Management LLC Takes $1.07 Million Position in LifeStance Health Group, Inc. $LFST

Militia Capital Management LLC acquired a new position in LifeStance Health Group, Inc. (NASDAQ:LFST) during the 1st quarter, HoldingsChannel.com reports. The firm acquired 167,444 shares of the company’s stock, valued at approximately $1,067,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in LifeStance Health Group by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after purchasing an additional 3,086,506 shares during the period. Silversmith Partners I GP LLC purchased a new position in shares of LifeStance Health Group during the fourth quarter worth $100,842,000. Dimensional Fund Advisors LP boosted its position in shares of LifeStance Health Group by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock worth $66,038,000 after buying an additional 1,461,215 shares during the period. Jennison Associates LLC grew its stake in shares of LifeStance Health Group by 38.5% in the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after buying an additional 2,843,388 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of LifeStance Health Group by 27.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,118,027 shares of the company’s stock valued at $43,071,000 after buying an additional 1,324,691 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Stock Down 1.8%

Shares of NASDAQ LFST opened at $10.81 on Friday. The stock has a market cap of $4.19 billion, a P/E ratio of 180.17 and a beta of 1.12. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. LifeStance Health Group, Inc. has a 12-month low of $3.74 and a 12-month high of $11.76. The business’s fifty day simple moving average is $9.27 and its 200-day simple moving average is $7.79.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.The firm had revenue of $403.48 million during the quarter, compared to analyst estimates of $387.46 million. LifeStance Health Group’s revenue for the quarter was up 21.2% on a year-over-year basis. As a group, equities analysts predict that LifeStance Health Group, Inc. will post 0.12 EPS for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In other news, Director Eric Shuey sold 243,362 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the completion of the transaction, the director directly owned 867,562 shares of the company’s stock, valued at approximately $6,957,847.24. The trade was a 21.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Darren M. Black sold 5,899,661 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the sale, the director owned 23,310,115 shares in the company, valued at $186,947,122.30. The trade was a 20.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,687,394 shares of company stock valued at $63,579,701 in the last quarter. Corporate insiders own 3.50% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on LFST. Wall Street Zen raised LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. The Goldman Sachs Group initiated coverage on shares of LifeStance Health Group in a research note on Friday, June 5th. They set a “neutral” rating and a $9.00 price target on the stock. Barclays raised their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Finally, Canaccord Genuity Group lifted their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, LifeStance Health Group has an average rating of “Moderate Buy” and an average target price of $11.12.

LifeStance Health Group Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.